Home » Topics » Science » Drug design, drug delivery and technologies

Drug design, drug delivery and technologies
RSS

International team identifies selective P2X antagonists

Aug. 21, 1998

MorphoSys and Pharmacia & Upjohn suspend joint research program

Aug. 20, 1998

Genzyme division and Bayer enter into genomics agreement

Aug. 20, 1998

Genome Therapeutics and Cadus join forces in the search for new therapeutic targets

Aug. 19, 1998

Matrix granted Japanese patent; U.S. patent reissued

Aug. 18, 1998

MorphoSys and DuPont Pharmaceuticals sign collaboration agreement

Aug. 14, 1998

Fusion protein enables large-scale production of bioactive carbohydrates

Aug. 14, 1998

Idun to license patent application for apoptosis model

Aug. 13, 1998

Gene screening technology developed at Harvard Medical School licensed to Versicor

Aug. 10, 1998

Label expansion for CEPRATE SC approved

July 31, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...